Fig. 3. CHST11 is an AR repressed gene.

a ChIP-seq AR binding intensity within indicated CHST11 genomic region in LNCaP and VCaP cells (Cistrome.com; WashU Epigenome Browser) (⁵⁰, ⁵¹). b qPCR analysis using three sets of CHST11 primers designed around the Chr 12:104625188 location, after CHIP of AR in LNCaP cells in CSS media in presence or absence of R1881. TMPRSS2, FKBP5, and PSA validated primers around the ARE were used as positive controls. c Identified CHST11 ARE, mutated and deleted sequences. d BLI assay where biotinylated AR-DNA binding domain was immobilized sensor and incubated in presence of CHST11 ARE sequences listed in c, KLK3-ARE sequence used as positive control. Representative data of 3 independent experiments. e Levels of CHST11 transcripts by q-PCR in LNCaP cells after 72 h of androgen deprivation (AD) condition and 48 h of treatment with R1881 and/or Enzalutamide normalized to FBS condition. n = 3 independent biological samples; mean ± SD; FBS vs. AD p < 0.0001; AD vs. AD + R1881 [1 nM] p = 0.0006; AD vs. AD + R1881 [10 nM] p = 0.0002; AD + R1881 [10 nM] vs. AD + R1881 [10 nM] +Enzalutamide p = 0.0314. One-way ANOVA followed by Tukey correction *p < 0.05; ***p < 0.001). f Protein levels of PSA, CHST11, and AR in LNCaP cells in FBS or AD condition ± R1881 (1, 5, 10 nM); representative of three independent experiments. g Protein levels of CHST11 and CHST13 in AR + and AR- PC cell lines. The CHST11 antibody detected additional uncharacterized bands at ~30 kDa (see Source data file); representative of four independent experiments. h CHST11 and CHST13 protein levels in PC3 after AR ectopic expression for 72 h. LNCaP lysate was used as reference. Experiment performed in duplicate. Source data are provided as a Source Data file.